RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration…
RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration…
Saint-Herblain (France), October 11, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty…
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company…
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company…
PALO ALTO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
PALO ALTO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Poster presentations highlight preclinical data from Ryvu’s PRMT5 program in MTAP-Deficient cancers and its synthetic…
New Principal Investigators at Velocity Clinical Research. From left to right: Shilpa Muthusamy, MD, Matt…
PALO ALTO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
PALO ALTO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
DELRAY BEACH, Fla.–(BUSINESS WIRE)–Everynet, one of the world’s largest network operators for national LoRaWAN® networks,…
BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an…
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company…
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Epic Bio, a biotechnology company…
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Aarhus, Denmark, 26…
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an…
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome…